A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients : A Universal Effort to Preserve Patients' Lives and Allografts
The coronavirus disease 2019 (COVID-19) pandemic has posed a significant challenge to physicians and healthcare systems worldwide. Evidence about kidney transplant (KTx) recipients is still limited. A systematic literature review was performed. We included 63 articles published from 1 January until 7 July 2020, reporting on 420 adult KTx recipients with confirmed COVID-19. The mean age of patients was 55 ± 15 years. There was a male predominance (67%). The majority (74%) were deceased donor recipients, and 23% were recently transplanted (<1 year). Most patients (88%) had at least one comorbidity, 29% had two, and 18% three. Ninety-three percent of cases were hospitalized. Among them, 30% were admitted to the intensive care unit, 45% developed acute respiratory distress syndrome, and 44% had acute kidney injury with 23% needing renal replacement therapy. From the hospitalized patients a total of 22% died, 59% were discharged, and 19% were still in hospital at the time of publication. Immunosuppression was reduced in 27%, discontinued in 31%, and remained unchanged in 5%. Hydroxychloroquine was administered to 78% of patients, antibiotics to 73%, and antivirals to 30% while 25% received corticosteroid boluses, 28% received anti-interleukin agents, and 8% were given immunoglobulin. The main finding of our analysis was that the incidence of COVID-19 among kidney transplant patients is not particularly high, but when they do get infected, this is related to significant morbidity and mortality.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Journal of clinical medicine - 9(2020), 9 vom: 16. Sept. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Marinaki, Smaragdi [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 infection |
---|
Anmerkungen: |
Date Revised 28.10.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/jcm9092986 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM315192135 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM315192135 | ||
003 | DE-627 | ||
005 | 20231225154357.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/jcm9092986 |2 doi | |
028 | 5 | 2 | |a pubmed24n1050.xml |
035 | |a (DE-627)NLM315192135 | ||
035 | |a (NLM)32947798 | ||
035 | |a (PII)E2986 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Marinaki, Smaragdi |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients |b A Universal Effort to Preserve Patients' Lives and Allografts |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.10.2020 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a The coronavirus disease 2019 (COVID-19) pandemic has posed a significant challenge to physicians and healthcare systems worldwide. Evidence about kidney transplant (KTx) recipients is still limited. A systematic literature review was performed. We included 63 articles published from 1 January until 7 July 2020, reporting on 420 adult KTx recipients with confirmed COVID-19. The mean age of patients was 55 ± 15 years. There was a male predominance (67%). The majority (74%) were deceased donor recipients, and 23% were recently transplanted (<1 year). Most patients (88%) had at least one comorbidity, 29% had two, and 18% three. Ninety-three percent of cases were hospitalized. Among them, 30% were admitted to the intensive care unit, 45% developed acute respiratory distress syndrome, and 44% had acute kidney injury with 23% needing renal replacement therapy. From the hospitalized patients a total of 22% died, 59% were discharged, and 19% were still in hospital at the time of publication. Immunosuppression was reduced in 27%, discontinued in 31%, and remained unchanged in 5%. Hydroxychloroquine was administered to 78% of patients, antibiotics to 73%, and antivirals to 30% while 25% received corticosteroid boluses, 28% received anti-interleukin agents, and 8% were given immunoglobulin. The main finding of our analysis was that the incidence of COVID-19 among kidney transplant patients is not particularly high, but when they do get infected, this is related to significant morbidity and mortality | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a COVID-19 infection | |
650 | 4 | |a immunosuppression | |
650 | 4 | |a kidney transplantation | |
650 | 4 | |a outcomes | |
650 | 4 | |a treatment | |
700 | 1 | |a Tsiakas, Stathis |e verfasserin |4 aut | |
700 | 1 | |a Korogiannou, Maria |e verfasserin |4 aut | |
700 | 1 | |a Grigorakos, Konstantinos |e verfasserin |4 aut | |
700 | 1 | |a Papalois, Vassilios |e verfasserin |4 aut | |
700 | 1 | |a Boletis, Ioannis |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 9(2020), 9 vom: 16. Sept. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2020 |g number:9 |g day:16 |g month:09 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm9092986 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2020 |e 9 |b 16 |c 09 |